Design, synthesis, and biological evaluation of novel 6-aminoalkyl- and 7-heteroaryl substituted 7-deazapurine nucleoside analogs against SARS-CoV-2 replication.

IF 4 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Antiviral research Pub Date : 2025-10-01 Epub Date: 2025-08-07 DOI:10.1016/j.antiviral.2025.106246
Guoqiang Yao, Xue Shi, Hao Jiang, Anna Duan, Jiancun Zhang
{"title":"Design, synthesis, and biological evaluation of novel 6-aminoalkyl- and 7-heteroaryl substituted 7-deazapurine nucleoside analogs against SARS-CoV-2 replication.","authors":"Guoqiang Yao, Xue Shi, Hao Jiang, Anna Duan, Jiancun Zhang","doi":"10.1016/j.antiviral.2025.106246","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the declaration by the WHO on May 5th of 2023 that the COVID-19 epidemic no longer constitutes a Public Health Emergency of International Concern (PHEIC), it continues to pose a significant threat to human health due to ongoing viral mutations. Although multiple vaccines and drugs have received approval for the prevention and treatment of COVID-19, effectively controlling the epidemic continues to be challenging, emphasizing the necessity for the development of new and more effective antivirals. In this work, we report the design and synthesis of a series of novel 7-alkynyl-7-deazapurine nucleoside analogs and some of their corresponding prodrugs as potential inhibitors of SARS-CoV-2 replication. The biological activities were evaluated and a reasonable structure-activity relationship (SAR) was revealed. Among the compounds, compound 54 (EC<sub>50</sub> = 0.71 μM) and 30c (EC<sub>50</sub> = 0.66 μM) may serve as potential candidates for further development.</p>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":" ","pages":"106246"},"PeriodicalIF":4.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.antiviral.2025.106246","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the declaration by the WHO on May 5th of 2023 that the COVID-19 epidemic no longer constitutes a Public Health Emergency of International Concern (PHEIC), it continues to pose a significant threat to human health due to ongoing viral mutations. Although multiple vaccines and drugs have received approval for the prevention and treatment of COVID-19, effectively controlling the epidemic continues to be challenging, emphasizing the necessity for the development of new and more effective antivirals. In this work, we report the design and synthesis of a series of novel 7-alkynyl-7-deazapurine nucleoside analogs and some of their corresponding prodrugs as potential inhibitors of SARS-CoV-2 replication. The biological activities were evaluated and a reasonable structure-activity relationship (SAR) was revealed. Among the compounds, compound 54 (EC50 = 0.71 μM) and 30c (EC50 = 0.66 μM) may serve as potential candidates for further development.

新型抗SARS-CoV-2复制的6-氨基烷基和7-杂芳基取代7-去氮杂嘌呤核苷类似物的设计、合成和生物学评价
尽管世界卫生组织于2023年5月5日宣布COVID-19流行病不再构成国际关注的突发公共卫生事件(PHEIC),但由于病毒持续突变,它继续对人类健康构成重大威胁。尽管已有多种疫苗和药物获得批准用于预防和治疗COVID-19,但有效控制疫情仍然具有挑战性,这强调了开发新的更有效的抗病毒药物的必要性。在这项工作中,我们设计和合成了一系列新的7-烷基基-7-去氮杂嘌呤核苷类似物及其相应的一些前药,作为SARS-CoV-2复制的潜在抑制剂。对其生物活性进行了评价,揭示了合理的构效关系。其中化合物54 (EC50 = 0.71 μM)和30c (EC50 = 0.66 μM)可能是进一步开发的候选化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antiviral research
Antiviral research 医学-病毒学
CiteScore
17.10
自引率
3.90%
发文量
157
审稿时长
34 days
期刊介绍: Antiviral Research is a journal that focuses on various aspects of controlling viral infections in both humans and animals. It is a platform for publishing research reports, short communications, review articles, and commentaries. The journal covers a wide range of topics including antiviral drugs, antibodies, and host-response modifiers. These topics encompass their synthesis, in vitro and in vivo testing, as well as mechanisms of action. Additionally, the journal also publishes studies on the development of new or improved vaccines against viral infections in humans. It delves into assessing the safety of drugs and vaccines, tracking the evolution of drug or vaccine-resistant viruses, and developing effective countermeasures. Another area of interest includes the identification and validation of new drug targets. The journal further explores laboratory animal models of viral diseases, investigates the pathogenesis of viral diseases, and examines the mechanisms by which viruses avoid host immune responses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信